Adenocarcinoma: Clinical Trials

8,258 trials for Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3233 completed, 1431 unknown, 1317 recruiting, 854 terminated. 3239 Phase 2, 1727 Phase 1, 1309 Not applicable, 690 Phase 3, 171 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 23239Completed 1253, Recruiting 511, Unknown 466, Terminated 441, Active not recruiting 236, Not yet recruiting 157, Withdrawn 151, Suspended 18, Enrolling by invitation 6
Phase 11727Completed 732, Terminated 270, Recruiting 266, Unknown 189, Active not recruiting 138, Withdrawn 69, Not yet recruiting 45, Suspended 15, Enrolling by invitation 3
Not applicable1309Completed 439, Unknown 302, Recruiting 235, Terminated 99, Not yet recruiting 95, Active not recruiting 65, Withdrawn 60, Enrolling by invitation 9, Suspended 5
Phase 3690Completed 253, Unknown 134, Recruiting 90, Active not recruiting 72, Terminated 72, Not yet recruiting 36, Withdrawn 27, Suspended 5, Enrolling by invitation 1
Phase 4171Completed 66, Unknown 58, Recruiting 19, Not yet recruiting 11, Terminated 9, Active not recruiting 3, Withdrawn 3, Enrolling by invitation 2
Early Phase 1117Completed 43, Unknown 17, Recruiting 15, Withdrawn 12, Terminated 11, Not yet recruiting 9, Active not recruiting 8, Suspended 2

Follow Adenocarcinoma: new trials by email Literature Review of Adenocarcinoma trials Research Report on Adenocarcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma
Not applicableNot yet recruitingJonsson Comprehensive Cancer Center1002027-09-022026-10-19
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)162027-05-172026-10-21
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Phase 2Not yet recruitingNorthwestern University562027-05-052026-10-07
Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Phase 2Not yet recruitingBeth Israel Deaconess Medical Center102027-04-262026-11-09
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
RayAblation - Liver Tumors
Not applicableNot yet recruitingM.D. Anderson Cancer Center2002027-04-012026-10-16
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingMedSIR442027-03-012026-11-04
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 3Not yet recruitingNational Cancer Institute (NCI)4002027-02-102026-07-08
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center202027-02-072026-09-18
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma
Phase 2Not yet recruitingFujian Cancer Hospital272027-02-012026-10-01
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
Zolbetuximab Exposure, Platinum-based Chemotherapy Exposure, 1L Treatment Not Containing Zolbetuximab Exposure - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Not yet recruitingAstellas Pharma Europe Ltd.10002027-01-312026-10-28
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus
Phase 4Not yet recruitingEunice Dube21402027-01-302026-07-30
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer
Phase 3Not yet recruitingNRG Oncology52702027-01-302026-09-30
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Ivonescimab, IP PTX - Phase II, Ivonescimab
Phase 2Not yet recruitingM.D. Anderson Cancer Center302027-01-162026-08-27
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC)
Phase 3Not yet recruitingUNICANCER9902027-01-022026-08-04
NK521 in the Treatment of Advanced Solid Tumors
NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer
Early Phase 1Not yet recruitingBase Therapeutics (Shanghai) Co., Ltd.182027-01-012026-09-30
Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention
Cooking Healthy - Engaging Families (CHEF), Control - Neoplams, Prostate Cancer (Adenocarcinoma)
Not applicableNot yet recruitingUniversity of Arizona402027-01-012026-07-14

Showing 20 of 8258. Sign in to see all of them.

Narrower conditions

Carcinoma, Hepatocellular (3384)  ·  Carcinoma, Renal Cell (1964)  ·  Cholangiocarcinoma (780)  ·  Carcinoma, Non-Small-Cell Lung (741)  ·  Liver Neoplasms (602)  ·  Breast Neoplasms (529)  ·  Kidney Neoplasms (505)  ·  Neoplasms (491)  ·  Lung Neoplasms (458)  ·  Pancreatic Neoplasms (430)  ·  Melanoma (408)  ·  Adenocarcinoma of Lung (404)  ·  Neoplasm Metastasis (404)  ·  Colorectal Neoplasms (385)

Broader conditions

Neoplasms, Glandular and Epithelial (8225)  ·  Neoplasms by Histologic Type (8220)  ·  Carcinoma (8082)  ·  Neoplasms (7767)  ·  Neoplasms by Site (7267)  ·  Digestive System Diseases (4356)  ·  Digestive System Neoplasms (4299)  ·  Liver Diseases (3408)  ·  Liver Neoplasms (2856)  ·  Urogenital Diseases (2402)  ·  Urogenital Neoplasms (2341)  ·  Female Urogenital Diseases and Pregnancy Complications (2281)  ·  Female Urogenital Diseases (2268)  ·  Male Urogenital Diseases (2196)

Interventions

Sorafenib (323)  ·  pembrolizumab (311)  ·  Bevacizumab (301)  ·  Nivolumab (272)  ·  Gemcitabine (253)  ·  lenvatinib (233)  ·  Cisplatin (214)  ·  Oxaliplatin (172)  ·  Sunitinib (168)  ·  Fluorouracil (164)  ·  Radiotherapy (162)  ·  Carboplatin (148)  ·  Radiosurgery (143)  ·  Magnetic Resonance Spectroscopy (134)  ·  Capecitabine (130)

Sponsors

National Cancer Institute (NCI) (329)  ·  Sun Yat-sen University (197)  ·  M.D. Anderson Cancer Center (155)  ·  Fudan University (94)  ·  Pfizer (89)  ·  Memorial Sloan Kettering Cancer Center (87)  ·  Seoul National University Hospital (82)  ·  Novartis Pharmaceuticals (79)  ·  Shanghai Zhongshan Hospital (78)  ·  Mayo Clinic (68)  ·  Bayer (64)  ·  Assistance Publique - Hôpitaux de Paris (56)  ·  National Taiwan University Hospital (53)  ·  University Health Network, Toronto (53)  ·  Alliance for Clinical Trials in Oncology (51)

Countries

United States (3415)  ·  China (1860)  ·  France (725)  ·  South Korea (556)  ·  Italy (552)  ·  Canada (483)  ·  Spain (468)  ·  Germany (452)  ·  United Kingdom (429)  ·  Taiwan (409)  ·  Australia (309)  ·  Netherlands (277)  ·  Japan (262)  ·  Belgium (261)  ·  Poland (189)

Top investigators

Ming Shi, MD (23)  ·  Jeong Min Lee, MD (14)  ·  Tim F Greten, M.D. (13)

Results publications

PMID 37146227, PMID 40812353, PMID 12049862, PMID 27238653, PMID 28410911, PMID 29433850, PMID 11981766, PMID 20375404, PMID 12540794, PMID 18650514, PMID 19192962, PMID 19095497, PMID 22551107, PMID 25577718, PMID 29628281, PMID 29875066, PMID 30207593, PMID 32402160, PMID 33526329, PMID 34143971, PMID 36852452, PMID 12091661, PMID 16757203, PMID 19097774, PMID 21374666, PMID 27932229, PMID 29471013, PMID 31401903, PMID 32499241, PMID 32557715, PMID 32716739, PMID 33058158, PMID 33538338, PMID 34905388, PMID 36410913, PMID 37097003, PMID 39462179, PMID 14667750, PMID 17960615, PMID 19766639, PMID 21612974, PMID 22980441, PMID 23964934, PMID 26361969, PMID 26702763, PMID 26706103, PMID 27279544, PMID 28434648, PMID 30998813, PMID 31070690

NIH funding

2023 (61), 2016 (45), 2018 (39), 2019 (37), U10CA032102 (37), P30CA033572 (35), 2025 (32), 2015 (28), P30CA016672 (28), U10CA031946 (27), 2017 (26), P30CA015083 (23), 2014 (22), P30CA043703 (22), P30CA060553 (21)